"目录号: HY-15224
Cell Cycle/DNA DamageEpigenetics-
PCI-34051 是一种有效的选择性的HDAC8抑制剂，IC50为 10 nM。
相关产品
Trichostatin A-Panobinostat-Vorinostat-Entinostat-Mocetinostat-Belinostat-ACY-1215-Valproic acid sodium salt-Romidepsin-Quisinostat-Sodium Butyrate-RGFP966-Sirtinol-Chidamide-Parthenolide-
生物活性
Description
PCI-34051 is a potent and selectiveHDAC8inhibitor withIC50of 10 nM, with >200-fold selectivity over the other HDAC isoforms.
IC50& Target
IC50: 10 nM (HDAC8), 2.9 μM (HDAC6), 4 μM (HDAC1), 13 μM (HDAC10)[1]
In Vitro
PCI-34051 inhibits pure recombinant HDAC8 with Kiof 10 nM with >200-fold selectivity over the other HDACs tested, including HDACs 1, 2, 3, 6 and 10. PCI-34051 is derived from a low molecular weight hydroxamic acid scaffold that possessed promising potency (HDAC8; Ki=2 μM) and selectivity (approximately fivefold) for HDAC8 relative to the other class I HDACs. PCI-34051 is found to induce apoptosis at low micromolar concentrations in cell lines derived from T-cell lymphomas, including Jurkat and HuT78, whereas doses as high as 20 μM has no effect on B-cell- or myeloid-derived lymphomas or solid tumor lines[1].
In Vivo
Administration of PCI-34051 and Dexamethasone reduces the eosinophilic inflammation and airway hyperresponsiveness in asthma to reduce the airway remodeling[2].
References
